95 related articles for article (PubMed ID: 27876270)
1. A new manufacturing process to remove thrombogenic factors (II, VII, IX, X, and XI) from intravenous immunoglobulin gamma preparations.
Park DH; Kang GB; Kang DE; Hong JW; Lee MG; Kim KY; Han JW
Biologicals; 2017 Jan; 45():1-8. PubMed ID: 27876270
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the ability of the Privigen® purification process to deplete thrombogenic factor XIa from plasma.
Komenda M; Stadler D; Malinas T; Moses M; Pragst I; Herzog E; Schmutz P; Minnig K; El Menyawi I
Vox Sang; 2014 Jul; 107(1):26-36. PubMed ID: 24329163
[TBL] [Abstract][Full Text] [Related]
3. In vitro evaluation of residual procoagulants in human intravenous immunoglobulins from 11 Chinese blood fractionation companies.
Ma L; Sun P; Lin F; Diao G; Li C
Thromb Res; 2013 Sep; 132(3):381-5. PubMed ID: 23953595
[TBL] [Abstract][Full Text] [Related]
4. Cation exchange chromatography removes FXIa from a 10% intravenous immunoglobulin preparation.
Kang GB; Huber A; Lee J; Kim MJ; Bang E; Hong J; Park S
Front Cardiovasc Med; 2023; 10():1253177. PubMed ID: 38075963
[TBL] [Abstract][Full Text] [Related]
5. Quantitative determination of activated coagulation factor XI as an impurity in therapeutic immunoglobulins from Chinese blood fractionation companies.
Ma L; Sun P; Lin FZ; Diao G; Li CQ
Genet Mol Res; 2013 Jul; 12(3):2556-61. PubMed ID: 23315876
[TBL] [Abstract][Full Text] [Related]
6. Flebogamma(®) DIF (intravenous immunoglobulin) purification process effectively eliminates procoagulant activities.
José M; Marzo N; Pons B; Herrerias A; López L; Faro M; López M; Jorquera JI
Biologicals; 2013 Nov; 41(6):393-9. PubMed ID: 24051302
[TBL] [Abstract][Full Text] [Related]
7. Absence of in vitro Procoagulant Activity in Immunoglobulin Preparations due to Activated Coagulation Factors.
Oviedo AE; Bernardi ME; Guglielmone HA; Vitali MS
Transfus Med Hemother; 2015 Nov; 42(6):397-402. PubMed ID: 26733772
[TBL] [Abstract][Full Text] [Related]
8. Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations.
Wolberg AS; Kon RH; Monroe DM; Hoffman M
Am J Hematol; 2000 Sep; 65(1):30-4. PubMed ID: 10936860
[TBL] [Abstract][Full Text] [Related]
9. Identification of kallikrein and FXIa as impurities in therapeutic immunoglobulins: implications for the safety and control of intravenous blood products.
Etscheid M; Breitner-Ruddock S; Gross S; Hunfeld A; Seitz R; Dodt J
Vox Sang; 2012 Jan; 102(1):40-6. PubMed ID: 21545600
[TBL] [Abstract][Full Text] [Related]
10. Determination of procoagulant activity in human normal immunoglobulin preparations for therapeutic use by FXIa chromogenic assay: Evaluation of test kit sensitivity, reference standard performance and product formulation effects on the FXIa assay.
Behr-Gross ME; Le Tallec D; Sinitskaya N; Milne C; Etscheid M
Pharmeur Bio Sci Notes; 2024; 2024():27-75. PubMed ID: 38533680
[TBL] [Abstract][Full Text] [Related]
11. Quantifying the thrombogenic potential of human plasma-derived immunoglobulin products.
Germishuizen WA; Gyure DC; Stubbings D; Burnouf T
Biologicals; 2014 Sep; 42(5):260-70. PubMed ID: 25096922
[TBL] [Abstract][Full Text] [Related]
12. Significance of platelet and monocyte activation for therapeutic immunoglobulin-induced thromboembolism.
Salge-Bartels U; Heiden M; Groß N; Seitz R
Thromb Res; 2014 Feb; 133(2):244-53. PubMed ID: 24342536
[TBL] [Abstract][Full Text] [Related]
13. Enabling accurate measurement of activated factor XI (FXIa) in therapeutic immunoglobulin products.
Wilmot HV; Gray E
Vox Sang; 2021 Jul; 116(6):656-664. PubMed ID: 33277936
[TBL] [Abstract][Full Text] [Related]
14. Assessment of immunoglobulin concentrates on thrombogenic activity by thrombin generation assay, prekallikrein activator assay, and size-exclusion chromatography.
Seifner A; Beck G; Bayer P; Eichmeir S; Lackner F; Rögelsperger O; Weber K; Wollein G
Transfusion; 2014 Feb; 54(2):376-83. PubMed ID: 23772713
[TBL] [Abstract][Full Text] [Related]
15. Development of an intravenous immunoglobulin with improved safety and functional activity.
Roberts PL; Dolan T; Paddick M; Stagg S; More JE
Biologicals; 2015 Mar; 43(2):123-9. PubMed ID: 25498751
[TBL] [Abstract][Full Text] [Related]
16. Detecting factor XIa in immune globulin products: Commutability of international reference materials for traditional and global hemostasis assays.
Liang Y; Jackson JW; Woodle SA; Surov SS; Parunov LA; Scott DE; Weinstein M; Lee TK; Ovanesov MV
Res Pract Thromb Haemost; 2021 Jan; 5(1):211-222. PubMed ID: 33537546
[TBL] [Abstract][Full Text] [Related]
17. Human plasma-derived immunoglobulin G fractionated by an aqueous two-phase system, caprylic acid precipitation, and membrane chromatography has a high purity level and is free of detectable in vitro thrombogenic activity.
Vargas M; Segura Á; Wu YW; Herrera M; Chou ML; Villalta M; León G; Burnouf T
Vox Sang; 2015 Feb; 108(2):169-77. PubMed ID: 25469648
[TBL] [Abstract][Full Text] [Related]
18. Thromboembolic events associated with immunoglobulin treatment.
Funk MB; Gross N; Gross S; Hunfeld A; Lohmann A; Guenay S; Hanschmann KM; Keller-Stanislawski B
Vox Sang; 2013 Jul; 105(1):54-64. PubMed ID: 23398249
[TBL] [Abstract][Full Text] [Related]
19. Human coagulation factor IX: assessment of thrombogenicity in animal models and viral safety.
Herring SW; Abildgaard C; Shitanishi KT; Harrison J; Gendler S; Heldebrant CM
J Lab Clin Med; 1993 Mar; 121(3):394-405. PubMed ID: 8445288
[TBL] [Abstract][Full Text] [Related]
20. [Contamination of IgG preparation for intravenous use with IgA. II. Removal of IgA1 from IgG preparation using affinity chomatography on lectin jacalin columns].
Dovezenski N; Velicković Z; Tosić Lj; Nikolić G; Popović O; Romić M; Djokić M; Mijusković Z
Srp Arh Celok Lek; 1994; 122 Suppl 1():51-2. PubMed ID: 18173187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
